Pacific Biosciences Of California (PACB) Convertible Debt (2021 - 2026)

Pacific Biosciences Of California's Convertible Debt history runs 6 years deep, the most recent figure standing at $644.1 million for Q1 2026.

• In Q1 2026, Convertible Debt changed 0.33% year-over-year to $644.1 million; the TTM figure through Mar 2026 stood at $644.1 million (changed 0.33% YoY), while the FY2025 annual figure was $645.4 million, changed 0.33% from the prior year.
• Convertible Debt was $644.1 million for Q1 2026 at Pacific Biosciences Of California, roughly flat from $645.4 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $896.8 million in Q1 2023 to a low of $644.1 million in Q1 2026.
• Historically, Convertible Debt has averaged $806.6 million across 5 years, with a median of $892.2 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Convertible Debt climbed 0.13% in 2024, then dropped 27.77% in 2025.
• A 5-year view of Convertible Debt shows it stood at $896.7 million in 2022, then slipped by 0.5% to $892.2 million in 2023, then slipped by 27.43% to $647.5 million in 2024, then dropped by 0.33% to $645.4 million in 2025, then decreased by 0.2% to $644.1 million in 2026.
• The last three Convertible Debt figures came in at $644.1 million (Q1 2026), $645.4 million (Q4 2025), and $645.2 million (Q3 2025), per Business Quant data.